Incyte Corporation (INCY)
-NasdaqGS 20.36 
1.05(4.90%) 3:59PM EDT
| Prev Close: | 21.41 |
|---|
| Open: | 21.32 |
|---|
| Bid: | N/A |
|---|
| Ask: | 23.15 x 200 |
|---|
| 1y Target Est: | 25.21 |
|---|
| Beta: | 1.43 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 20.31 - 21.60 |
|---|
| 52wk Range: | 15.43 - 26.30 |
|---|
| Volume: | 1,419,147 |
|---|
| Avg Vol (3m): | 1,083,450 |
|---|
| Market Cap: | 2.76B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.11 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Positive Data on Novartis' JakaviZacks(Tue, Jun 18)
- Positive Data on Incyte's JakafiZacks(Tue, Jun 18)
- Successor To Humira? AbbVie And Galapagos Work On Itat Seeking Alpha(Mon, Jun 17)
- InPlay: Incyte Incyte drug Jakafi improved overall survival in Phase III trial of patients with myelofibrosisBriefing.com(Mon, Jun 17)
- Incyte Drug Jakafi® (ruxolitinib) Improved Overall Survival in Phase III Trial of Patients with MyelofibrosisBusiness Wire(Sun, Jun 16)
- Positive Data on Incyte/LLY's BaricitinibZacks(Fri, Jun 14)
- Incyte's Jakafi Label UpdatedZacks(Thu, Jun 13)
- Incyte Jakafi outlook still positive after label revisions, says Oppenheimertheflyonthewall.com(Thu, Jun 13)
- Incyte Jakafi label update expected, says UBStheflyonthewall.com(Thu, Jun 13)
- Lilly says arthritis pill effective in mid-stage studyat Reuters(Thu, Jun 13)
- Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid ArthritisPR Newswire(Thu, Jun 13)
- Jakafi® (ruxolitinib) Prescribing Information Updated with Expanded Dosing Guidance and New Safety InformationBusiness Wire(Wed, Jun 12)
- When It Comes To Biotech, Diversity Is Keyat Seeking Alpha(Wed, Jun 12)
- Incyte's Management Presents at Goldman Sachs 34th Annual Global Healthcare Conference - Transcriptat Seeking Alpha(Wed, Jun 12)
- Commit To Purchase Incyte Corporation At $12.50, Earn 10.8%at Forbes(Mon, Jun 10)
Key Statistics
| Forward P/E (1 yr): | 254.50 |
|---|
| P/S (ttm): | 8.76 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.13 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.08 |
|---|
| Mean Recommendation*: | 1.9 |
|---|
| PEG Ratio (5 yr expected): | -1.76 |
|---|
Business Summary
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation.
View More